Multilevel/JJ
Precision-Based/JJ
Rational/JJ
Design/JJ
of/IN
Chemical/JJ
Inhibitors/NNS
Targeting/VBG
the/DT
Hydrophobic/JJ
Cleft/NN
of/IN
Toxoplasma/NN
gondii/NN
Apical/JJ
Membrane/NN
Antigen/NN
1/CD
(/(
AMA1/NN
)/)
./.
====================
Toxoplasma/NN
gondii/NN
is/VBZ
an/DT
intracellular/JJ
Apicomplexan/NN
parasite/NN
and/CC
a/DT
causative/JJ
agent/NN
of/IN
toxoplasmosis/NN
in/IN
human/JJ
./.
====================
It/PRP
causes/VBZ
encephalitis/NN
,/,
uveitis/NN
,/,
chorioretinitis/NN
,/,
and/CC
congenital/JJ
infection/NN
./.
====================
T./FW
gondii/NN
invades/VBZ
the/DT
host/NN
cell/NN
by/IN
forming/VBG
a/DT
moving/JJ
junction/NN
(/(
MJ/NN
)/)
complex/NN
./.
====================
This/DT
complex/NN
formation/NN
is/VBZ
initiated/VBN
by/IN
intermolecular/JJ
interactions/NNS
between/IN
the/DT
two/CD
secretory/JJ
parasitic/JJ
proteins—namely/RB
,/,
apical/JJ
membrane/NN
antigen/NN
1/CD
(/(
AMA1/NN
)/)
and/CC
rhoptry/NN
neck/NN
protein/NN
2/CD
(/(
RON2/NN
)/)
and/CC
is/VBZ
critically/RB
essential/JJ
for/IN
the/DT
host/NN
invasion/NN
process/NN
./.
====================
By/IN
this/DT
study/NN
,/,
we/PRP
propose/VBP
two/CD
potential/JJ
leads/VBZ
,/,
NSC95522/NN
and/CC
NSC179676/NN
that/DT
can/MD
efficiently/RB
target/NN
the/DT
AMA1/NN
hydrophobic/JJ
cleft/NN
,/,
which/WDT
is/VBZ
a/DT
hotspot/NN
for/IN
targeting/VBG
MJ/NN
complex/NN
formation/NN
./.
====================
The/DT
proposed/JJ
leads/VBZ
are/VBP
the/DT
result/NN
of/IN
an/DT
exhaustive/JJ
conformational/JJ
search-based/VBN
virtual/JJ
screen/NN
with/IN
multilevel/JJ
precision/NN
scoring/VBG
of/IN
the/DT
docking/NN
affinities/NNS
./.
====================
These/DT
two/CD
compounds/NNS
surpassed/VBD
all/DT
the/DT
precision/NN
levels/NNS
of/IN
docking/NN
and/CC
also/RB
the/DT
stringent/JJ
post/JJ
docking/NN
and/CC
cumulative/JJ
molecular/JJ
dynamics/NNS
evaluations/NNS
./.
====================
Moreover/RB
,/,
the/DT
backbone/NN
flexibility/NN
of/IN
hotspot/NN
residues/NNS
in/IN
the/DT
hydrophobic/JJ
cleft/NN
,/,
which/WDT
has/VBZ
been/VBN
previously/RB
reported/VBD
to/TO
be/VB
essential/JJ
for/IN
accommodative/JJ
binding/VBG
of/IN
RON2/NN
to/TO
AMA1/NN
,/,
was/VBD
also/RB
highly/RB
perturbed/VBN
by/IN
these/DT
compounds/NNS
./.
====================
Furthermore/RB
,/,
binding/VBG
free/JJ
energy/NN
calculations/NNS
of/IN
these/DT
two/CD
compounds/NNS
also/RB
revealed/VBD
a/DT
significant/JJ
affinity/NN
to/TO
AMA1/NN
./.
====================
Machine/NN
learning/VBG
approaches/NNS
also/RB
predicted/VBN
these/DT
two/CD
compounds/NNS
to/TO
possess/VB
more/RBR
relevant/JJ
activities/NNS
./.
====================
Hence/RB
,/,
these/DT
two/CD
leads/VBZ
,/,
NSC95522/NN
and/CC
NSC179676/NN
,/,
may/MD
prove/VB
to/TO
be/VB
potential/JJ
inhibitors/NNS
targeting/VBG
AMA1-RON2/NN
complex/NN
formation/NN
towards/IN
combating/VBG
toxoplasmosis/NN
./.
====================
Toxoplasma/NN
gondii/NN
is/VBZ
an/DT
Apicomplexan/NN
intracellular/JJ
parasite/NN
and/CC
is/VBZ
a/DT
causative/JJ
agent/NN
of/IN
toxoplasmosis/NN
in/IN
human/JJ
./.
====================
It/PRP
also/RB
plays/VBZ
a/DT
key/JJ
role/NN
over/IN
a/DT
broad/JJ
spectrum/NN
of/IN
clinical/JJ
syndromes/NNS
,/,
like/IN
encephalitis/NN
,/,
uveitis/NN
,/,
chorioretinitis/NN
,/,
and/CC
congenital/JJ
infections/NNS
[/(
1/CD
]/)
./.
====================
It/PRP
infects/VBZ
the/DT
host/NN
by/IN
various/JJ
modes/NNS
,/,
such/JJ
as/IN
intake/JJ
of/IN
undercooked/JJ
meat/NN
containing/VBG
T./FW
gondii/NN
cysts/NNS
,/,
consumption/NN
of/IN
contaminated/JJ
water/NN
,/,
and/CC
food/NN
defilement/JJ
with/IN
feces/NNS
from/IN
infected/JJ
cats/NNS
,/,
and/CC
may/MD
also/RB
spread/VBN
through/IN
blood/NN
transfusion/NN
[/(
23/CD
]/)
./.
====================
The/DT
sexual/JJ
reproduction/NN
of/IN
T./FW
gondii/NN
occurs/VBZ
in/IN
domestic/JJ
cats/NNS
,/,
which/WDT
are/VBP
considered/VBN
a/DT
definite/JJ
host/NN
[/(
4/CD
]/)
./.
====================
The/DT
asexual/JJ
reproduction/NN
of/IN
this/DT
parasite/NN
occurs/VBZ
in/IN
intermediate/JJ
hosts—namely/RB
,/,
humans/NNS
,/,
cattle/NN
,/,
and/CC
birds/VBZ
[/(
5/CD
]/)
./.
====================
The/DT
establishment/NN
of/IN
host-parasite/NN
interactions/NNS
is/VBZ
crucial/JJ
for/IN
parasite/NN
survival/NN
,/,
as/IN
it/PRP
depends/VBZ
on/IN
host/NN
nutritive/JJ
resources/VBZ
./.
====================
Apicomplexan/RB
parasites/NNS
implement/JJ
a/DT
unique/JJ
host/NN
cell/NN
invasion/NN
mechanism/NN
,/,
wherein/IN
they/PRP
anchor/NN
the/DT
host/NN
cell/NN
by/IN
forming/VBG
multimeric/JJ
protein/NN
machinery/NN
,/,
called/VBN
a/DT
moving/JJ
junction/NN
(/(
MJ/NNP
)/)
complex/NN
[/(
6/CD
]/)
./.
====================
This/DT
complex/NN
is/VBZ
formed/VBN
by/IN
interprotein/JJ
interactions/NNS
established/VBN
between/IN
two/CD
types/NNS
of/IN
proteins-namely/RB
,/,
rhoptry/NN
neck/NN
proteins/NNS
2/4/5/8/CD
(/(
RON/NN
2/CD
,/,
4/CD
,/,
5/CD
,/,
and/CC
8/CD
)/)
proteins/NNS
secreted/VBN
by/IN
rhoptry/NN
organelle/NN
of/IN
the/DT
parasite/JJ
onto/IN
the/DT
host/NN
membrane/NN
and/CC
apical/JJ
membrane/NN
antigen/NN
1/CD
(/(
AMA1/NN
)/)
,/,
secreted/VBN
by/IN
micronemes/NNS
[/(
789/CD
]/)
./.
====================
The/DT
molecular/JJ
association/NN
of/IN
RON2/NN
and/CC
AMA1/NN
is/VBZ
essential/JJ
for/IN
initiating/VBG
the/DT
host/NN
invasion/NN
process/NN
./.
====================
AMA1/NN
hydrophobic/JJ
cleft/NN
====================
The/DT
hydrophobic/JJ
cleft/NN
region/NN
of/IN
AMA1/NN
is/VBZ
documented/VBN
to/TO
play/VB
a/DT
predominant/JJ
role/NN
in/IN
facilitating/VBG
the/DT
binding/NN
of/IN
RON2/NN
to/TO
AMA1/NN
and/CC
is/VBZ
also/RB
reinforced/VBD
by/IN
recent/JJ
crystallographic/JJ
studies/NNS
on/IN
AMA1-RON2/NN
complex/NN
formation/NN
[/(
10/CD
]/)
./.
====================
Moreover/RB
,/,
this/DT
region/NN
is/VBZ
found/VBN
to/TO
be/VB
highly/RB
conserved/VBN
across/IN
the/DT
diverse/JJ
family/NN
of/IN
AMA1/NN
proteins/NNS
and/CC
is/VBZ
surrounded/VBN
by/IN
polymorphic/JJ
flexible/JJ
loops/NNS
./.
====================
These/DT
loops/NNS
are/VBP
speculated/VBN
to/TO
preclude/VB
the/DT
host/NN
antibody/NN
response/NN
and/CC
has/VBZ
also/RB
been/VBN
found/VBN
to/TO
guard/JJ
the/DT
conserved/VBN
sites/NNS
in/IN
AMA1/NN
[/(
11/CD
]/)
./.
====================
The/DT
hydrophobic/JJ
cleft/NN
is/VBZ
found/VBN
to/TO
span/VB
within/IN
domain/NN
I/NN
of/IN
AMA1/NN
and/CC
forms/NNS
a/DT
binding/VBG
pocket/NN
that/DT
receives/VBZ
the/DT
critical/JJ
loop/NN
region/NN
of/IN
RON2/NN
due/JJ
to/TO
its/PRP$
accommodative/JJ
shape/VBP
and/CC
charge/JJ
complementarity/NN
./.
====================
The/DT
hydrophobic/JJ
cleft/NN
region/NN
of/IN
AMA1/NN
includes/VBZ
15/CD
residues/NNS
(/(
Val142/NN
,/,
Leu155/NNP
,/,
Ile161/NN
,/,
Phe163/NN
,/,
Ile171/NN
,/,
Phe174/NN
,/,
Leu179/NNP
,/,
Ile185/NN
,/,
Phe197/NN
,/,
Met203/NNP
,/,
Tyr230/NN
,/,
Val231/NN
,/,
Trp253/NNP
,/,
Trp353/NNP
,/,
and/CC
Trp354/NN
)/)
[/(
12/CD
]/)
./.
====================
Recent/JJ
studies/NNS
illustrate/VBP
that/DT
RON2/NN
displaces/VBZ
a/DT
loop/NN
in/IN
domain/NN
II/CD
of/IN
AMA1/NN
,/,
thereby/RB
exposing/VBG
its/PRP$
binding/VBG
surface/NN
,/,
enabling/VBG
the/DT
RON2/NN
loop/NN
to/TO
penetrate/VB
deep/RB
into/IN
the/DT
hydrophobic/JJ
groove/NN
of/IN
AMA1/NN
and/CC
hence/RB
forming/VBG
a/DT
stable/JJ
complex/NN
during/IN
host/NN
invasion/NN
[/(
13/CD
]/)
./.
====================
A/DT
recent/JJ
study/NN
also/RB
showed/VBD
that/IN
an/DT
oligopeptide/JJ
binds/VBZ
across/IN
the/DT
full/JJ
length/NN
of/IN
the/DT
AMA1/NN
hydrophobic/JJ
cleft/NN
to/TO
prevent/VB
AMA1-RON2/NN
complex/NN
formation/NN
and/CC
eventually/RB
blocks/VBZ
parasitic/JJ
host/NN
invasion/NN
[/(
1415/CD
]/)
./.
====================
Hence/RB
,/,
the/DT
hydrophobic/JJ
cleft/NN
and/CC
its/PRP$
surrounding/VBG
loops/NNS
,/,
which/WDT
include/VBP
the/DT
cysteine/NN
loop/NN
region/NN
and/CC
coil/JJ
connector/NN
,/,
have/VBP
been/VBN
proposed/VBN
to/TO
be/VB
a/DT
critical/JJ
hotspot/NN
to/TO
block/VB
AMA1-RON2/NN
complex/NN
formation/NN
./.
====================
To/TO
date/NN
,/,
there/EX
is/VBZ
a/DT
paucity/NN
of/IN
data/NNS
on/IN
small/JJ
molecules/NNS
targeting/VBG
these/DT
interactions/NNS
./.
====================
Hence/RB
,/,
in/IN
this/DT
study/NN
,/,
the/DT
coordinates/NNS
of/IN
the/DT
crystal/JJ
structure/NN
complex/NN
depicting/VBG
these/DT
interactions/NNS
(/(
Protein/NN
Data/NNS
Bank/NN
[/(
PDB/NN
]/)
ID/NN
2Y8T/JJ
,/,
AMA1/NN
interacting/VBG
with/IN
a/DT
surface-exposed/JJ
region/NN
of/IN
RON2/NN
)/)
[/(
16/CD
]/)
were/VBD
subjected/VBN
to/TO
an/DT
exhaustive/JJ
,/,
multilevel/JJ
precision/NN
high-throughput/JJ
virtual/JJ
screen/RB
(/(
HTVS/NN
)/)
of/IN
ligands/NNS
from/IN
the/DT
National/JJ
Cancer/NN
Institute/RB
(/(
NCI/NN
)/)
database/NN
with/IN
250,000/CD
compounds/NNS
to/TO
identify/VB
leads/VBZ
that/IN
potentially/RB
disrupt/VBP
these/DT
interactions/NNS
./.
====================
We/PRP
also/RB
implemented/VBD
molecular/JJ
dynamics/NNS
(/(
MD/NN
)/)
simulation/JJ
analysis/NN
to/TO
decipher/DT
the/DT
backbone/NN
rigidity/NN
changes/NNS
of/IN
AMA1/NN
hotspot/NN
residues/NNS
,/,
machine/NN
learning-based/VBD
activity/NN
prediction/NN
,/,
and/CC
binding/VBG
free/JJ
energy/NN
calculations/NNS
for/IN
finalizing/VBG
the/DT
potential/JJ
lead/VBP
compounds/NNS
towards/IN
combating/VBG
toxoplasmosis/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
[/(
17/CD
]/)
./.
====================
Protein/NN
preparation/NN
====================
As/IN
an/DT
initial/JJ
step/NN
,/,
the/DT
crystal/JJ
coordinates/VBZ
of/IN
AMA1/NN
in/IN
complex/NN
with/IN
a/DT
surface-exposed/JJ
region/NN
of/IN
RON2/NN
(/(
PDB/NN
ID/NN
:/:
2Y8T/JJ
)/)
was/VBD
pre-processed/VBN
using/VBG
Protein/NN
Preparation/NN
Wizard/JJ
of/IN
the/DT
Schrödinger/NNP
(/(
New/NN
York/NN
,/,
NY/NNP
,/,
USA/NNP
)/)
suite/JJ
towards/IN
optimizing/VBG
the/DT
stereochemistry/NN
by/IN
assigning/VBG
proper/JJ
bond/NN
order/NN
,/,
removing/VBG
steric/JJ
clashes/NNS
,/,
adding/VBG
hydrogen/NN
atoms/NNS
,/,
fixing/VBG
the/DT
disulfide/NN
bonds/NNS
and/CC
missing/VBG
residues/NNS
and/CC
loops/VBZ
./.
====================
Furthermore/RB
,/,
optimization/NN
of/IN
the/DT
protein/NN
structure/NN
was/VBD
also/RB
performed/VBN
by/IN
adjusting/VBG
the/DT
terminal/JJ
chi/NN
rotation/NN
of/IN
asparagine/NN
,/,
glutamine/NN
,/,
and/CC
histidine/NN
residues/NNS
./.
====================
Optimal/JJ
protonation/NN
states/NNS
for/IN
histidine/NN
residues/NNS
were/VBD
also/RB
assigned/VBD
,/,
followed/VBN
by/IN
the/DT
removal/NN
of/IN
unwanted/JJ
hetero/NN
groups/NNS
./.
====================
Finally/RB
,/,
energy/NN
minimization/NN
was/VBD
performed/VBN
with/IN
OPLS_2005/NN
(/(
Schrödinger/NNP
)/)
to/TO
obtain/VB
the/DT
optimal/JJ
geometry/NN
./.
====================
Receptor/NN
grid/NN
generation/NN
for/IN
exhaustive/JJ
search/VBP
====================
The/DT
receptor/NN
grid/NN
for/IN
docking/NN
was/VBD
generated/VBN
by/IN
assigning/VBG
the/DT
entire/JJ
hydrophobic/JJ
cleft/NN
region/NN
of/IN
AMA1/NN
to/TO
which/WDT
the/DT
RON2/NN
binds/VBZ
,/,
thereby/RB
performing/VBG
an/DT
exhaustive/JJ
cavity/NN
search/VBP
towards/IN
achieving/VBG
an/DT
optimal/JJ
ligand/NN
binding/NN
pose/VBP
./.
====================
The/DT
residues/NNS
spanning/VBG
the/DT
RON2/NN
binding/NN
cavity/NN
were/VBD
noted/VBN
from/IN
the/DT
Dimplot/NN
generated/VBN
for/IN
the/DT
AMA1-RON2/NN
complex/NN
[/(
16/CD
]/)
./.
====================
The/DT
van/NN
der/NN
Waals/NNS
radii/NN
for/IN
the/DT
receptor/NN
were/VBD
assigned/VBN
with/IN
a/DT
scaling/NN
factor/NN
of/IN
1.0/CD
and/CC
a/DT
partial/JJ
cutoff/JJ
of/IN
0.25/CD
./.
====================
The/DT
grid-assigned/JJ
residues/NNS
were/VBD
Leu99/NN
,/,
Val105/NN
,/,
Leu109/NNP
,/,
Tyr110/NN
,/,
Arg111/NN
,/,
Val142/NN
,/,
Phe143/NN
,/,
Thr144/NNP
,/,
Glu145/NN
,/,
Leu155/NNP
,/,
Asn162/NN
,/,
Thr165/NNP
,/,
Gln169/NN
,/,
Arg170/NN
,/,
Ile171/NN
,/,
Asn182/NN
,/,
Asn184/NN
,/,
Leu200/NNP
,/,
Thr201/NN
,/,
Val202/NN
,/,
Ala203/NN
,/,
Met204/NNP
,/,
Tyr213/NN
,/,
Tyr215/NN
,/,
Tyr230/NN
,/,
Ser232/NN
,/,
Met233/NNP
,/,
Met236/NNP
,/,
Tyr241/NN
,/,
Thr252/NN
,/,
Trp253/NNP
,/,
Gln338/NN
,/,
Phe339/NN
,/,
and/CC
Gln361/NN
./.
====================
Ligand/NN
preparation/NN
====================
To/TO
expedite/VB
the/DT
virtual/JJ
screening/NN
of/IN
ligands/NNS
,/,
the/DT
NCI/NN
ligand/NN
datasets/NNS
(/(
250,000/CD
compounds/NNS
)/)
were/VBD
screened/VBN
for/IN
drug-likeness/JJ
by/IN
implementing/VBG
the/DT
Lipinski/NN
rule/JJ
./.
====================
The/DT
filtered/JJ
molecules/NNS
were/VBD
optimized/VBN
by/IN
the/DT
LigPrep/JJ
module/NN
(/(
Schrödinger/NNP
)/)
by/IN
fixing/VBG
the/DT
ring/NN
isomers/NNS
,/,
stereoisomers/NNS
,/,
and/CC
tautomeric/JJ
forms/NNS
./.
====================
The/DT
reactive/JJ
functional/JJ
groups/NNS
were/VBD
also/RB
removed/VBD
,/,
and/CC
the/DT
resultants/NNS
were/VBD
scaled/VBN
for/IN
van/NN
der/NN
Waals/NNS
radii/NN
with/IN
a/DT
scaling/JJ
factor/NN
of/IN
0.80/CD
and/CC
a/DT
partial/JJ
charge/JJ
cutoff/JJ
of/IN
0.15/CD
./.
====================
Finally/RB
,/,
the/DT
compounds/NNS
passing/VBG
all/DT
these/DT
filters/NNS
were/VBD
energy-minimized/VBN
with/IN
OPLS_2005/NN
as/IN
the/DT
force/NN
field/NN
./.
====================
Multilevel/JJ
precision-based/VBD
virtual/JJ
screening/NN
====================
The/DT
in/FW
silico/NN
virtual/JJ
screening/NN
and/CC
docking/NN
of/IN
optimized/VBN
NCI/NN
compounds/NNS
against/IN
AMA1/NN
were/VBD
performed/VBN
using/VBG
the/DT
Glide/NN
HTVS/NN
option/NN
of/IN
the/DT
Schrodinger/NNP
suite/JJ
2012/CD
(/(
Schrödinger/NNP
,/,
LLC/NN
)/)
./.
====================
As/IN
a/DT
first/JJ
step/NN
,/,
the/DT
entire/JJ
RON2-interacting/JJ
cavity/NN
was/VBD
fixed/JJ
as/IN
a/DT
grid/JJ
box/NN
./.
====================
The/DT
van/NN
der/NN
Waals/NNS
radius/NN
scaling/VBG
was/VBD
set/NN
to/TO
1.0/CD
to/TO
allow/VB
free/JJ
scaling/NN
to/TO
soften/JJ
the/DT
non-polar/JJ
regions/NNS
of/IN
the/DT
receptor/NN
and/CC
the/DT
rest/JJS
of/IN
the/DT
other/JJ
atoms/NNS
./.
====================
Finally/RB
,/,
the/DT
optimized/VBN
small/JJ
molecules/NNS
were/VBD
successively/RB
docked/VBD
to/TO
AMA1/NN
,/,
ensuring/VBG
flexible/JJ
sampling/NN
with/IN
no/DT
more/RBR
than/IN
300/CD
atoms/NNS
and/CC
50/CD
rotatable/JJ
bonds/NNS
./.
====================
A/DT
total/JJ
of/IN
10/CD
energetically/RB
favorable/JJ
conformations/NNS
were/VBD
selected/VBN
among/IN
the/DT
1,000/CD
generated/VBN
poses/VBZ
per/IN
docking/NN
,/,
and/CC
the/DT
best/JJS
docked/VBD
complexes/NNS
were/VBD
finalized/VBN
,/,
based/VBN
on/IN
the/DT
Glide/NN
docking/NN
score/RB
./.
====================
During/IN
the/DT
screening/NN
process/NN
,/,
successive/JJ
elimination/NN
of/IN
ligand/NN
hits/VBZ
was/VBD
performed/VBN
through/IN
three/CD
filtering/VBG
modes/NNS
using/VBG
the/DT
Schrödinger/NNP
suite/JJ
:/:
100/CD
%/NN
of/IN
HTVS/NN
hits/VBZ
were/VBD
passed/VBN
to/TO
standard/JJ
precision/NN
(/(
SP/NN
)/)
,/,
and/CC
80/CD
%/NN
of/IN
the/DT
best/JJS
hits/VBZ
from/IN
SP/NN
were/VBD
passed/VBN
to/TO
extra/JJ
precision/NN
(/(
XP/NN
)/)
mode/NN
./.
====================
The/DT
top/NN
10/CD
hits/VBZ
in/IN
XP/NN
,/,
based/VBN
on/IN
Glide/NN
score/RB
,/,
were/VBD
shortlisted/VBN
for/IN
further/JJ
validation/NN
[/(
18/CD
]/)
./.
====================
Prediction/NN
of/IN
Activity/NN
Spectra/NN
of/IN
Substances/NNS
prediction/NN
====================
The/DT
putative/JJ
activities/NNS
of/IN
the/DT
top/NN
10/CD
compounds/NNS
were/VBD
predicted/VBN
using/VBG
Prediction/NN
of/IN
Activity/NN
Spectra/NN
of/IN
Substances/NNS
(/(
PASS/NN
)/)
./.
====================
It/PRP
implements/VBZ
a/DT
machine/JJ
learning-based/VBD
algorithm/NN
called/VBN
biological/JJ
activity/NN
spectrum/NN
(/(
with/IN
95/CD
%/NN
accuracy/NN
)/)
,/,
and/CC
it/PRP
works/VBZ
by/IN
describing/VBG
the/DT
intrinsic/JJ
properties/NNS
of/IN
the/DT
compounds/NNS
and/CC
by/IN
comparing/VBG
the/DT
structure/NN
of/IN
the/DT
new/JJ
compound/NN
with/IN
the/DT
structure/NN
of/IN
well-known/JJ
biologically/RB
active/JJ
substances/NNS
to/TO
check/VB
whether/IN
the/DT
new/JJ
compound/NN
exhibits/VBZ
any/DT
of/IN
the/DT
specific/JJ
functional/JJ
effects/NNS
[/(
19/CD
]/)
./.
====================
Among/IN
the/DT
10/CD
shortlisted/JJ
compounds/NNS
,/,
four/CD
showed/VBD
significant/JJ
activity/NN
relevant/JJ
towards/IN
suppressing/VBG
toxoplasmosis/NN
,/,
along/IN
with/IN
a/DT
favorable/JJ
Glide/NN
docking/NN
score/RB
./.
====================
Hence/RB
,/,
these/DT
four/CD
compounds/NNS
were/VBD
subjected/VBN
to/TO
a/DT
rigorous/JJ
validation/NN
process/NN
of/IN
calculating/JJ
Molecular/JJ
Mechanics/NNS
Generalized/JJ
Born/NNP
Surface/NN
Area/NN
(/(
MMGBSA/NN
)/)
score/VBP
and/CC
by/IN
performing/VBG
an/DT
MD/NN
simulation/JJ
./.
====================
MMGBSA/NN
scoring/VBG
====================
MMGBSA/NN
scoring/VBG
was/VBD
performed/VBN
for/IN
the/DT
top/NN
4/CD
complexes/NNS
,/,
so/RB
as/IN
to/TO
calculate/JJ
and/CC
identify/VBP
binding/VBG
free/JJ
energies/VBZ
in/IN
an/DT
explicit-solvent/JJ
exposed/VBN
state/NN
by/IN
implementing/VBG
the/DT
Prime/NN
module/NN
of/IN
the/DT
Schrodinger/NNP
suite/JJ
./.
====================
A/DT
more/RBR
negative/JJ
MMBGSA/NN
score/NN
indicates/VBZ
stronger/JJR
binding/NN
[/(
20/CD
]/)
./.
====================
MD/NN
simulation/NN
====================
MD/NN
simulation/NN
for/IN
both/DT
apo/NN
and/CC
the/DT
docked/VBN
complexes/NNS
was/VBD
performed/VBN
using/VBG
Desmond/JJ
3.6/CD
./.
====================
The/DT
simulation/JJ
was/VBD
initiated/VBN
using/VBG
the/DT
OPLS_2005/NN
[/(
21/CD
]/)
force/VBP
field/NN
with/IN
the/DT
system/NN
solvated/JJ
using/VBG
the/DT
simple/JJ
point/NN
charge/NN
water/NN
model/NN
./.
====================
The/DT
system/NN
was/VBD
neutralized/VBN
by/IN
adding/VBG
4/CD
Na+/JJ
for/IN
apo/NN
and/CC
6/CD
Na+/JJ
counter/NN
ions/NNS
for/IN
complexes/NNS
at/IN
a/DT
concentration/NN
of/IN
4.751/CD
mM/NN
./.
====================
Further/RB
,/,
this/DT
system/NN
was/VBD
energy-minimized/VBN
with/IN
OPLS_2005/NN
./.
====================
The/DT
SHAKE/JJ
algorithm/NN
was/VBD
applied/VBN
to/TO
restrain/VB
the/DT
geometry/NN
of/IN
water/NN
molecules/NNS
and/CC
bond/NN
lengths/NNS
and/CC
bond/NN
angles/NNS
of/IN
heavy/JJ
atoms/NNS
[/(
22/CD
]/)
./.
====================
Periodic/JJ
boundary/NN
conditions/NNS
were/VBD
applied/VBN
to/TO
stimulate/VB
a/DT
continuous/JJ
system/NN
[/(
23/CD
]/)
and/CC
the/DT
particle/NN
mesh/JJ
Ewald/JJ
method/NN
for/IN
long-range/JJ
electrostatics/NNS
[/(
24/CD
]/)
./.
====================
Further/RB
,/,
the/DT
system/NN
was/VBD
equilibrated/JJ
with/IN
NPT/NN
ensemble/JJ
by/IN
setting/VBG
the/DT
temperature/NN
and/CC
pressure/NN
parameters/NNS
to/TO
300/CD
K/NN
and/CC
1.0/CD
bar/JJ
,/,
respectively/RB
./.
====================
The/DT
Berendsen/JJ
coupling/NN
algorithm/NN
was/VBD
chosen/NN
for/IN
temperature-pressure/NN
coupling/NN
[/(
25/CD
]/)
./.
====================
Further/RB
,/,
the/DT
equilibrated/JJ
system/NN
,/,
with/IN
a/DT
total/JJ
of/IN
74,931/CD
atoms/NNS
,/,
was/VBD
exposed/VBN
to/TO
a/DT
simulation/JJ
period/NN
of/IN
5,000/CD
ps/NNS
with/IN
a/DT
time/NN
step/NN
of/IN
2/CD
fs/NNS
,/,
and/CC
trajectories/VBZ
were/VBD
recorded/VBN
after/IN
every/RB
1.0/CD
ps/NNS
./.
====================
The/DT
root/NN
mean/NN
square/VBP
deviation/NN
(/(
RMSD/NN
)/)
was/VBD
calculated/VBN
for/IN
the/DT
backbone/NN
atoms/NNS
and/CC
were/VBD
graphically/RB
analyzed/VBD
on/IN
a/DT
time/NN
point/NN
scale/NN
[/(
2627/CD
]/)
./.
====================
Similarly/RB
,/,
root/NN
mean/JJ
square/VBP
fluctuation/NN
(/(
RMSF/NN
)/)
for/IN
each/DT
residue/NN
was/VBD
also/RB
calculated/VBN
to/TO
compare/VB
the/DT
major/JJ
conformational/JJ
changes/NNS
in/IN
the/DT
residues/NNS
between/IN
apo/NN
and/CC
holo/JJ
forms/NNS
[/(
28/CD
]/)
./.
====================
The/DT
radius/JJ
of/IN
gyration/NN
(/(
Rg/NN
)/)
was/VBD
also/RB
calculated/VBN
to/TO
infer/VB
the/DT
compactness/NN
of/IN
the/DT
protein-ligand/NN
complex/NN
against/IN
the/DT
apo/NN
form/VBP
[/(
29/CD
]/)
./.
====================
Two-dimensional/JJ
intermolecular/JJ
interaction/NN
plots/NNS
depicting/VBG
the/DT
complex/NN
stability/NN
throughout/IN
the/DT
MD/NN
run/JJ
were/VBD
also/RB
generated/VBD
to/TO
infer/VB
the/DT
stability/NN
of/IN
the/DT
protein-ligand/NN
complex/NN
formation/NN
./.
====================
Multilevel/JJ
precision/NN
virtual/JJ
screening/NN
and/CC
docking/NN
analysis/NN
====================
Three/CD
different/JJ
stages/NNS
of/IN
the/DT
docking/NN
and/CC
scoring/VBG
processes/NNS
were/VBD
used/VBN
for/IN
this/DT
study/NN
,/,
beginning/VBG
with/IN
HTVS/NN
,/,
followed/VBN
by/IN
SP/NN
and/CC
final/JJ
scoring/VBG
with/IN
XP/NN
./.
====================
AMA1/NN
protein/NN
was/VBD
sequentially/RB
docked/VBD
with/IN
compounds/NNS
from/IN
the/DT
NCI/NN
database/NN
using/VBG
Schrodinger/NNP
Glide/NN
./.
====================
Initially/RB
,/,
HTVS/NN
was/VBD
performed/VBN
,/,
wherein/IN
146,670/CD
compounds/NNS
were/VBD
scored/VBN
as/IN
hits/VBZ
,/,
based/VBN
on/IN
Glide/NN
score/RB
./.
====================
Subsequently/RB
,/,
these/DT
compounds/NNS
were/VBD
passed/VBN
to/TO
SP/NN
mode/NN
,/,
which/WDT
yielded/VBD
1,466/CD
compounds/NNS
./.
====================
Finally/RB
,/,
within/IN
the/DT
SP/NN
resultant/JJ
hits/VBZ
,/,
147/CD
compounds/NNS
were/VBD
scored/VBN
as/IN
potential/JJ
hits/VBZ
in/IN
XP/NN
mode/NN
./.
====================
Further/RB
,/,
these/DT
compounds/NNS
were/VBD
ranked/VBN
in/IN
accordance/NN
with/IN
the/DT
XP/NN
docking/NN
score/RB
,/,
and/CC
the/DT
top/NN
10/CD
ranking/VBG
compounds/NNS
proceeded/VBD
to/TO
further/RBR
analysis/NN
./.
====================
These/DT
top/NN
10/CD
compounds/NNS
were/VBD
filtered/VBN
further/RBR
,/,
based/VBN
on/IN
Glide/NN
docking/NN
score/RB
,/,
significant/JJ
intermolecular/JJ
interactions/NNS
,/,
and/CC
PASS/NN
prediction/NN
./.
====================
Interestingly/RB
,/,
all/DT
10/CD
of/IN
these/DT
compounds/NNS
were/VBD
found/VBN
to/TO
occupy/VB
the/DT
hotspot/NN
region/NN
,/,
which/WDT
includes/VBZ
the/DT
hydrophobic/JJ
cleft/NN
and/CC
cysteine/NN
loop/NN
region/NN
of/IN
AMA1/NN
,/,
despite/IN
reference-guided/VBD
docking/NN
procedures/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
Receptor-ligand/CC
interaction/NN
studies/NNS
====================
Scoring/VBG
functions/NNS
play/VBP
a/DT
major/JJ
role/NN
in/IN
the/DT
docking/NN
process/NN
for/IN
identifying/VBG
plausible/JJ
ligand/NN
binding/NN
poses/VBZ
and/CC
also/RB
for/IN
ranking/VBG
the/DT
binding/NN
affinity/NN
./.
====================
Among/IN
the/DT
top/NN
10/CD
compounds/NNS
,/,
NSC95522/NN
,/,
NSC88253/NN
,/,
NSC13604/NN
,/,
and/CC
NSC179676/NN
(/(
Table/JJ
1/CD
,/,
Supplementary/JJ
Fig/NN
./.
====================
1/CD
)/)
were/VBD
found/VBN
to/TO
be/VB
highly/RB
significant/JJ
in/IN
collective/JJ
terms/NNS
of/IN
XP/NN
Glide/NN
score/RB
,/,
PASS/NN
prediction/NN
,/,
formation/NN
of/IN
intermolecular/JJ
H-bonds/NNS
,/,
and/CC
π-cation/NN
interactions/NNS
with/IN
the/DT
critical/JJ
hydrophobic/JJ
cleft/NN
residues/NNS
,/,
as/IN
well/RB
as/IN
in/IN
the/DT
cysteine/NN
loop/NN
region/NN
./.
====================
NSC95522/NN
showed/VBD
a/DT
Glide/NN
score/RB
of/IN
-10.564/CD
kcal/mol/NN
and/CC
formed/VBD
π-cation/NN
interactions/NNS
with/IN
Tyr110/NN
,/,
Tyr213/NN
,/,
and/CC
Tyr215/NN
,/,
stabilized/VBD
by/IN
3/CD
hydrogen/NN
bonds/NNS
formed/VBD
with/IN
Tyr230/NN
,/,
Ser232/NN
,/,
and/CC
Tyr215/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
1A/NN
)/)
./.
====================
Tyr230/NN
is/VBZ
a/DT
vital/JJ
residue/NN
in/IN
the/DT
hydrophobic/JJ
cleft/NN
,/,
as/IN
it/PRP
is/VBZ
the/DT
central/JJ
tyrosine/NN
of/IN
the/DT
apical/JJ
groove/NN
and/CC
is/VBZ
mandatory/JJ
for/IN
RON2/NN
binding/VBG
and/CC
also/RB
in/IN
the/DT
formation/NN
of/IN
a/DT
contiguous/JJ
surface/NN
,/,
which/WDT
is/VBZ
critical/JJ
for/IN
MJ/NN
assembly/RB
[/(
30/CD
]/)
./.
====================
Ser232/NN
is/VBZ
also/RB
documented/VBD
in/IN
Plasmodium/NN
falciparum/NN
as/IN
a/DT
key/JJ
hotspot/NN
residue/NN
,/,
as/IN
it/PRP
occupies/VBZ
the/DT
hydrophobic/JJ
cleft-spanning/VBG
region/NN
[/(
31/CD
]/)
./.
====================
Tyr213/NN
and/CC
Tyr215/NN
are/VBP
also/RB
crucial/JJ
,/,
as/IN
these/DT
residues/NNS
are/VBP
key/JJ
facilitators/NNS
of/IN
conformational/JJ
changes/NNS
in/IN
AMA1/NN
DII/NN
loop/NN
displacement/JJ
towards/IN
exposing/VBG
a/DT
clear/JJ
pocket/NN
to/TO
which/WDT
Pro1309/NN
of/IN
RON2/NN
docks/VBZ
to/TO
the/DT
triad/JJ
of/IN
tyrosine/NN
residues/NNS
(/(
Tyr110/142/NN
,/,
Tyr213/234/NN
,/,
and/CC
Tyr215/236/NN
)/)
during/IN
AMA1-RON2/NN
interactions/NNS
[/(
32/CD
]/)
./.
====================
PASS/NN
predicted/VBN
this/DT
compound/NN
to/TO
be/VB
an/DT
ophthalmic/JJ
drug/NN
and/CC
thus/RB
might/MD
also/RB
be/VB
found/VBN
to/TO
be/VB
effective/JJ
in/IN
treating/VBG
adverse/JJ
ocular-related/JJ
effects/NNS
due/JJ
to/TO
toxoplasmosis/NN
./.
====================
NSC88253/CD
was/VBD
bound/VBN
to/TO
the/DT
hydrophobic/JJ
cleft/NN
of/IN
AMA1/NN
with/IN
a/DT
XP/NN
Glide/NN
score/RB
of/IN
-10.392/CD
kcal/mol/NN
,/,
forming/VBG
almost/RB
similar/JJ
interactions/NNS
to/TO
that/DT
of/IN
the/DT
AMA1-NSC95522/NN
complex/NN
with/IN
3/CD
hydrogen/NN
bonds/NNS
:/:
2/CD
with/IN
the/DT
backbone/NN
of/IN
Tyr230/NN
and/CC
Ser232/NN
and/CC
1/CD
with/IN
the/DT
side/JJ
chain/NN
of/IN
Tyr215/NN
./.
====================
The/DT
π-cation/NN
interactions/NNS
with/IN
Tyr110/NN
and/CC
Tyr213/NN
were/VBD
also/RB
synonymously/RB
stabilized/VBD
by/IN
hydrogen/NN
bonds/NNS
formed/VBD
by/IN
residues/NNS
Tyr230/NN
,/,
Tyr215/NN
,/,
and/CC
Ser232/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
1B/NN
)/)
./.
====================
Tyr110/NN
is/VBZ
a/DT
coil/JJ
connector/NN
and/CC
is/VBZ
documented/VBN
to/TO
play/VB
an/DT
important/JJ
role/NN
in/IN
the/DT
displacement/JJ
of/IN
the/DT
DII/NN
loop/NN
of/IN
AMA1/NN
,/,
which/WDT
helps/VBZ
in/IN
the/DT
binding/NN
of/IN
RON2/NN
[/(
32/CD
]/)
./.
====================
PASS/NN
predicted/VBN
this/DT
compound/NN
to/TO
be/VB
an/DT
ophthalmic/JJ
drug/NN
with/IN
anticataract/JJ
and/CC
corneal/JJ
wound/NN
healing-stimulating/NN
activities/NNS
,/,
thus/RB
suggesting/VBG
it/PRP
to/TO
be/VB
an/DT
efficient/JJ
inhibitor/NN
targeting/VBG
ocular/JJ
toxoplasmosis/NN
./.
====================
NSC13604/NN
also/RB
showed/VBD
interactions/NNS
at/IN
the/DT
hydrophobic/JJ
cleft/NN
of/IN
AMA1/NN
,/,
with/IN
a/DT
XP/NN
Glide/NN
score/RB
of/IN
-10.016/CD
kcal/mol/NN
./.
====================
The/DT
docked/VBN
complex/NN
showed/VBD
2/CD
hydrogen/NN
bonds/NNS
with/IN
the/DT
peptide/NN
backbone/NN
of/IN
Met204/NN
,/,
which/WDT
occupies/VBZ
the/DT
cysteine/NN
loop/NN
region/NN
./.
====================
It/PRP
also/RB
formed/VBD
π-cation/NN
interactions/NNS
with/IN
Tyr213/NN
and/CC
Tyr110/NN
,/,
stabilized/VBD
by/IN
the/DT
hydrogen/NN
bonds/NNS
formed/VBD
with/IN
Met204/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
1D/CD
)/)
./.
====================
Met204/NN
is/VBZ
a/DT
key/JJ
residue/NN
for/IN
AMA1/NN
targeting/VBG
,/,
as/IN
it/PRP
is/VBZ
present/JJ
in/IN
the/DT
cysteine/NN
loop/NN
region/NN
,/,
which/WDT
is/VBZ
also/RB
a/DT
critical/JJ
substructure/NN
for/IN
AMA1-RON2/NN
complex/NN
formation/NN
./.
====================
As/IN
per/IN
previous/JJ
studies/NNS
,/,
disruption/NN
of/IN
the/DT
cysteine/NN
loop/NN
is/VBZ
found/VBN
to/TO
exhibit/VB
inefficiency/NN
in/IN
domain-II/NN
loop/NN
displacement/JJ
[/(
17/CD
]/)
./.
====================
PASS/NN
predicted/VBN
this/DT
compound/NN
to/TO
be/VB
antiprotozoal/JJ
and/CC
may/MD
prove/VB
it/PRP
to/TO
be/VB
efficient/JJ
in/IN
targeting/VBG
toxoplasmosis/NN
and/CC
also/RB
other/JJ
apicomplexans/NNS
./.
====================
NSC179676/CD
showed/VBD
interactions/NNS
with/IN
the/DT
hydrophobic/JJ
cleft/NN
,/,
with/IN
an/DT
XP/NN
score/RB
of/IN
-9.893/CD
kcal/mol/NN
./.
====================
It/PRP
formed/VBD
a/DT
single/JJ
hydrogen/NN
bond/NN
with/IN
the/DT
backbone/NN
Ser232/NN
,/,
which/WDT
is/VBZ
a/DT
critical/JJ
residue/NN
,/,
as/IN
discussed/VBN
earlier/RBR
./.
====================
It/PRP
also/RB
formed/VBD
π-cation/NN
interactions/NNS
with/IN
Tyr213/NN
and/CC
Tyr110/NN
(/(
Supplementary/NN
Fig/NN
./.
====================
1I/CD
)/)
./.
====================
PASS/NN
predicted/VBN
this/DT
molecule/NN
to/TO
be/VB
antiprotozoal/JJ
with/IN
corneal/JJ
wound/NN
healing-stimulating/NN
activities/NNS
./.
====================
These/DT
four/CD
compounds/NNS
exhibited/VBD
significant/JJ
features/NNS
in/IN
terms/NNS
of/IN
XP/NN
score/RB
,/,
key/JJ
molecular/JJ
interactions/NNS
,/,
and/CC
relevant/JJ
predicted/VBN
activity/NN
in/IN
comparison/NN
to/TO
rest/VB
of/IN
the/DT
compounds/NNS
./.
====================
Hence/RB
,/,
these/DT
compounds/NNS
in/IN
complex/NN
with/IN
AMA1/NN
were/VBD
further/RBR
validated/VBN
for/IN
stability/NN
of/IN
complex/NN
formation/NN
by/IN
implementing/VBG
MD/NN
simulation/JJ
./.
====================
MD/NN
simulation/NN
of/IN
apo/NN
and/CC
holo/NN
forms/NNS
====================
MD/NN
trajectory/JJ
analyses/NNS
were/VBD
performed/VBN
for/IN
apo/NN
and/CC
also/RB
for/IN
the/DT
4/CD
shortlisted/JJ
complexes/NNS
./.
====================
The/DT
backbone/NN
RMSD/NN
deviation/NN
of/IN
the/DT
apo/NN
form/VBP
of/IN
AMA1/NN
was/VBD
1.6/CD
Å/NN
,/,
which/WDT
has/VBZ
started/VBN
to/TO
equilibrate/JJ
and/CC
converge/VBP
after/IN
3,000/CD
ps/NNS
with/IN
a/DT
mean/JJ
of/IN
1.432/CD
Å/NNP
and/CC
a/DT
standard/JJ
deviation/NN
(/(
SD/NN
)/)
of/IN
0.178/CD
Å/NNP
./.
====================
The/DT
receptor/NN
RMSD/NN
for/IN
all/DT
4/CD
holo/JJ
forms/NNS
showed/VBD
convergence/NN
after/IN
the/DT
time/NN
frame/NN
ranging/VBG
between/IN
~3,000/CD
and/CC
4,000/CD
ps/NNS
,/,
with/IN
a/DT
maximum/JJ
mean/JJ
value/NN
of/IN
1.65/CD
Å/NN
and/CC
SD/NN
of/IN
0.27/CD
Å/NN
(/(
Fig/NN
./.
====================
2A/NN
)/)
./.
====================
Hence/RB
,/,
it/PRP
does/VBZ
not/RB
mandate/VB
an/DT
extended/JJ
production/NN
run/JJ
./.
====================
In/IN
the/DT
case/NN
of/IN
holo/JJ
forms/NNS
,/,
the/DT
ligand_RMSD/NN
for/IN
NSC95522/NN
,/,
NSC13604/NN
,/,
and/CC
NSC179676/NN
was/VBD
less/RBR
than/IN
2.5/CD
Å/NN
(/(
acceptable/JJ
range/NN
of/IN
1–3/CD
Å/NNP
)/)
[/(
33/CD
]/)
,/,
while/IN
NSC88253/NN
showed/VBD
3.6/CD
Å/NNP
of/IN
deviation/NN
,/,
inferring/VBG
complex/NN
instability/NN
(/(
Fig/NN
./.
====================
2B–F/CD
)/)
./.
====================
RMSF/NN
,/,
Rg/NN
,/,
and/CC
intermolecular/JJ
bond/NN
stability/NN
as/IN
a/DT
measure/NN
of/IN
shortlisting/VBG
potential/JJ
leads/VBZ
targeting/VBG
AMA1/NN
====================
The/DT
RMSF/NN
graph/NN
inferred/VBD
NSC95522/NN
and/CC
NSC179676/NN
to/TO
exhibit/VB
the/DT
least/JJS
fluctuation/NN
of/IN
</JJR
1/CD
Å/NN
at/IN
the/DT
critical/JJ
hotspot/NN
residues/NNS
(/(
Tyr230/NN
,/,
Tyr213/NN
,/,
Tyr15/NN
,/,
and/CC
Tyr110/NN
)/)
in/IN
comparison/NN
to/TO
the/DT
apo/NN
form/VBP
,/,
indicating/VBG
a/DT
gain/NN
of/IN
backbone/NN
rigidity/NN
./.
====================
As/IN
discussed/VBN
earlier/RBR
,/,
flexibility/NN
of/IN
these/DT
residues/NNS
is/VBZ
crucial/JJ
for/IN
homing/JJ
RON2/NN
./.
====================
However/RB
,/,
the/DT
other/JJ
two/CD
compounds/NNS
did/VBD
not/RB
show/VB
this/DT
impact/NN
(/(
Fig/NN
./.
====================
3A/NN
and/CC
3B/NN
)/)
./.
====================
Moreover/RB
,/,
the/DT
Rg/JJ
for/IN
both/DT
apo/JJ
and/CC
all/DT
4/CD
holo/RB
forms/VBZ
was/VBD
found/VBN
to/TO
be/VB
within/IN
an/DT
admissible/JJ
deviation/NN
of/IN
</JJR
1/CD
Å./NNP
NSC95522/NN
and/CC
NSC179676/NN
showed/VBD
the/DT
lowest/JJ
Rg/NNP
deviation/NN
of/IN
0.44/CD
Å/NNP
and/CC
0.53/CD
Å/NNP
,/,
while/IN
the/DT
apo/NN
form/VBP
showed/VBD
0.57/CD
Å/NNP
;/:
thus/RB
,/,
this/DT
reinforces/NNS
that/IN
these/DT
two/CD
compounds/NNS
confer/VBP
backbone/RB
rigidity/NN
and/CC
compactness/RB
,/,
which/WDT
strongly/RB
preclude/VBP
RON2/NN
binding/VBG
(/(
Fig/NN
./.
====================
3C/NN
)/)
./.
====================
Secondary/JJ
structure/NN
element/NN
(/(
SSE/NN
)/)
perturbations/NNS
were/VBD
also/RB
analyzed/VBD
in/IN
a/DT
similar/JJ
way/NN
as/IN
discussed/VBN
above/IN
./.
====================
This/DT
inferred/JJ
no/DT
major/JJ
dynamism/NN
in/IN
the/DT
SSE/NN
during/IN
the/DT
entire/JJ
production/NN
run/JJ
;/:
it/PRP
also/RB
corroborated/VBD
with/IN
the/DT
fewest/JJ
changes/NNS
observed/VBN
in/IN
the/DT
intra-molecular/JJ
hydrogen/NN
bonds/NNS
formed/VBD
for/IN
the/DT
apo/NN
and/CC
all/DT
other/JJ
4/CD
holo/JJ
forms/NNS
(/(
Fig/NN
./.
====================
3D/NN
)/)
./.
====================
For/IN
all/DT
four/CD
of/IN
these/DT
compounds/NNS
,/,
the/DT
stability/NN
of/IN
protein-ligand/CC
contacts/NNS
during/IN
the/DT
production/NN
run/JJ
was/VBD
analyzed/VBN
and/CC
visualized/VBD
as/IN
a/DT
2D/JJ
interaction/NN
map/VBP
(/(
Fig/NN
./.
====================
4A–D/CD
)/)
./.
====================
This/DT
inferred/JJ
π-cation/NN
interactions/NNS
to/TO
be/VB
unanimously/RB
stable/JJ
for/IN
all/DT
four/CD
compounds/NNS
./.
====================
Recent/JJ
studies/NNS
propose/VBP
that/IN
ligands/NNS
exhibiting/VBG
π-cation/NN
interactions/NNS
with/IN
Phe/NN
,/,
Tyr/NN
,/,
and/CC
Trp/JJ
of/IN
the/DT
receptor/NN
highly/RB
influence/VBP
the/DT
conformational/JJ
stability/NN
of/IN
the/DT
proteins/NNS
,/,
as/IN
they/PRP
are/VBP
strong/JJ
non-covalent/JJ
electrostatic/JJ
interactions/NNS
[/(
3435/CD
]/)
./.
====================
A/DT
holistic/JJ
and/CC
stringent/JJ
comparative/JJ
analysis/NN
was/VBD
performed/VBN
over/IN
the/DT
4/CD
holo/JJ
forms/NNS
against/IN
the/DT
apo/NN
form/VBP
,/,
which/WDT
strongly/RB
reinforces/VBZ
that/DT
AMA1-NSC95522/NN
and/CC
AMA1-NSC179676/NN
are/VBP
stable/JJ
complexes/NNS
./.
====================
Moreover/RB
,/,
both/CC
these/DT
compounds/NNS
exhibit/VBP
prominent/JJ
π-cation/NN
interactions/NNS
with/IN
the/DT
proven/JJ
hotspot/NN
residues/NNS
Tyr213/NN
,/,
Tyr230/NN
,/,
Tyr110/NN
,/,
and/CC
Tyr215/NN
of/IN
AMA1/NN
for/IN
~80/CD
%/NN
of/IN
the/DT
entire/JJ
production/NN
run/RB
,/,
implying/VBG
that/DT
these/DT
compounds/NNS
are/VBP
potential/JJ
blockers/NNS
of/IN
conformational/JJ
changes/NNS
of/IN
AMA1/NN
,/,
which/WDT
facilitates/VBZ
the/DT
binding/VBG
of/IN
RON2/NN
[/(
35/CD
]/)
./.
====================
The/DT
MMGBSA/NN
scores/VBZ
of/IN
the/DT
AMA1-NSC95522/NN
and/CC
AMA1-NSC179676/NN
complexes/NNS
were/VBD
found/VBN
to/TO
be/VB
-79/CD
kcal/mol/NN
and/CC
-59/CD
kcal/mol/NN
respectively/RB
,/,
also/RB
ensuring/VBG
significant/JJ
binding/NN
and/CC
stable/JJ
complex/NN
formation/NN
[/(
20/CD
]/)
./.
====================
In/IN
conclusion/NN
,/,
NSC95522/NN
and/CC
NSC179676/NN
shall/DT
be/VB
considered/VBN
the/DT
most/JJS
potential/JJ
leads/VBZ
,/,
with/IN
both/DT
showing/VBG
significant/JJ
binding/NN
free/JJ
energies/VBZ
with/IN
strong/JJ
intermolecular/JJ
interactions/NNS
to/TO
hydrophobic/JJ
cleft/NN
residues/NNS
./.
====================
Moreover/RB
,/,
these/DT
compounds/NNS
were/VBD
also/RB
found/VBD
to/TO
limit/VB
the/DT
torsion/NN
angle/JJ
of/IN
the/DT
AMA1/NN
tilt/JJ
of/IN
90°/CD
,/,
while/IN
the/DT
other/JJ
two/CD
compounds/NNS
showed/VBD
a/DT
wide/JJ
range/NN
of/IN
deviation/NN
(/(
~90°/CD
to/TO
180°/CD
)/)
./.
====================
Hence/RB
,/,
all/DT
of/IN
these/DT
inferences/NNS
strongly/RB
suggest/VBP
that/IN
NSC95522/NN
and/CC
NSC179676/NN
,/,
with/IN
antiprotozoal/JJ
and/CC
ophthalmic/JJ
activity/NN
,/,
shall/DT
prove/VB
to/TO
be/VB
highly/RB
efficient/JJ
leads/VBZ
for/IN
targeting/VBG
AMA1-RON2/NN
interactions/NNS
(/(
Fig/NN
./.
====================
4E/NN
)/)
,/,
thereby/RB
combating/VBG
toxoplasmosis/NN
./.
====================
However/RB
,/,
further/RBR
experimental/JJ
validation/NN
is/VBZ
required/VBN
to/TO
study/VB
the/DT
efficacy/NN
of/IN
these/DT
molecules/NNS
./.
====================
Schematic/JJ
representation/NN
of/IN
methodology/NN
of/IN
performing/VBG
an/DT
exhaustive/JJ
search/VBP
and/CC
stringent/JJ
validations/NNS
in/IN
identifying/VBG
potential/JJ
leads/VBZ
for/IN
combating/VBG
toxoplasmosis/NN
./.
====================
Multilevel/JJ
precision/NN
:/:
screens/NNS
the/DT
National/JJ
Cancer/NN
Institute/JJ
(/(
NCI/NN
)/)
ligands/NNS
based/VBN
on/IN
Glide/NN
docking/NN
score/NN
./.
====================
Molecular/JJ
Docking/JJ
:/:
identifies/VBZ
the/DT
favorable/JJ
interactions/NNS
formed/VBD
with/IN
the/DT
key/JJ
residues/NNS
./.
====================
Pass/NN
:/:
helps/VBZ
in/IN
discovering/VBG
additional/JJ
effects/NNS
of/IN
the/DT
top/NN
compounds/NNS
that/WDT
might/MD
favor/VB
in/IN
suppressing/VBG
the/DT
broad/JJ
spectrum/NN
of/IN
toxoplasmosis/NN
effects/NNS
./.
====================
Molecular/JJ
Mechanics/NNS
Generalized/JJ
Born/FW
Surface/NN
Area/NN
(/(
MMGBSA/NN
)/)
:/:
calculates/NNS
the/DT
free/JJ
energy/NN
binding/NN
./.
====================
Molecular/JJ
dynamics/NNS
:/:
evaluates/VBZ
the/DT
backbone/NN
stability/NN
,/,
fluctuation/NN
,/,
and/CC
compactness/VBP
of/IN
the/DT
complex/NN
./.
====================
HTVS/NN
,/,
high-throughput/JJ
virtual/JJ
screen/NN
;/:
PASS/NN
,/,
Prediction/NN
of/IN
Activity/NN
Spectra/NN
of/IN
Substances/NNS
;/:
RMSD/NN
,/,
root/NN
mean/JJ
square/VBP
deviation/NN
;/:
RMSF/NN
,/,
root/NN
mean/JJ
square/VBP
fluctuation/NN
;/:
SP/NN
,/,
standard/JJ
precision/NN
;/:
XP/NN
,/,
extra/JJ
precision/NN
./.
====================
(/(
A/NN
)/)
Root/NN
mean/NN
square/NN
deviation/NN
(/(
RMSD/NN
)/)
of/IN
apo/NN
against/IN
holo/JJ
forms/NNS
within/IN
2.5/CD
Å/NN
./.
====================
(/(
B/NN
,/,
D/NN
,/,
E/NN
)/)
Protein-ligand/NN
RMSD/NN
converged/VBD
within/IN
1~3/CD
Å/NN
./.
====================
(/(
C/NN
)/)
RMSD/NN
of/IN
NSC88253/NN
exhibited/VBD
instability/NN
with/IN
deviation/NN
of/IN
3.6/CD
Å/NN
./.
====================
(/(
F/NN
)/)
The/DT
RMSD/NN
score/NN
of/IN
the/DT
apo/NN
and/CC
holo/NN
forms/NNS
./.
====================
(/(
A/NN
)/)
The/DT
root/NN
mean/NN
square/NN
fluctuation/NN
(/(
RMSF/NN
)/)
fluctuations/NNS
of/IN
apo/NN
against/IN
holo/JJ
forms/NNS
./.
====================
(/(
B/NN
)/)
RMSF/NN
</JJR
1/CD
Å/NN
within/IN
hotspot/NN
residues/NNS
./.
====================
(/(
C/NN
)/)
Radius/NN
of/IN
gyration/NN
depicting/VBG
compactness/NN
of/IN
the/DT
apo/NN
and/CC
holo/NN
forms/NNS
./.
====================
(/(
D/NN
)/)
Intramolecular/JJ
H-bonds/NNS
showing/VBG
secondary/JJ
structure/NN
element/NN
stability/NN
./.
====================
(/(
A/NN
)/)
Interaction/NN
stability/NN
diagram/NN
for/IN
NSC95522/NN
showing/VBG
a/DT
stable/JJ
π-cation/NN
interaction/NN
with/IN
Tyr213/NN
and/CC
H-bond/JJ
interaction/NN
with/IN
Ser232/NN
./.
====================
(/(
B/NN
)/)
NSC88253/NN
did/VBD
not/RB
form/VB
any/DT
stable/JJ
interactions/NNS
during/IN
the/DT
production/NN
run/JJ
./.
====================
(/(
C/NN
)/)
NSC13604/NN
exhibited/VBD
a/DT
prominent/JJ
π-cation/NN
interaction/NN
with/IN
Tyr110/NN
./.
====================
(/(
D/NN
)/)
NSC179676/NN
displaced/JJ
a/DT
stable/JJ
π-cation/NN
interaction/NN
with/IN
Tyr230/NN
and/CC
Tyr110/NN
and/CC
water-mediated/VBD
H-bond/JJ
with/IN
Ser232/NN
./.
====================
(/(
E/NN
)/)
Three-dimensional/JJ
representation/NN
of/IN
ligands/NNS
NSC95522/NN
(/(
green/CD
)/)
and/CC
NSC179676/NN
(/(
magenta/NN
)/)
interacting/VBG
with/IN
the/DT
hotspot/NN
residue/NN
region/NN
(/(
blue/JJ
)/)
of/IN
apical/JJ
membrane/NN
antigen/NN
1/CD
./.
====================
Docking/VBG
molecular/JJ
interactions/NNS
of/IN
10/CD
best/JJS
compounds/NNS
with/IN
XP/NN
Glide/NN
score/RB
====================
